BioCentury
ARTICLE | Company News

Celldex GBM vaccine gets breakthrough designation

February 24, 2015 2:31 AM UTC

Celldex Therapeutics Inc. (NASDAQ:CLDX) jumped $3.52 (17%) to $24.73 on Monday after FDA granted breakthrough designation to Rintega rindopepimut ( CDX-110) to treat adults with EGFR variant III ( EGFRvIII)-positive recurrent glioblastoma multiforme.

Rintega, a vaccine targeting EGFRvIII, has Orphan Drug designation in the EU and U.S. for GBM and Fast Track designation in the U.S. ...